Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2022-03-24

Clinical Trial Update: Efficacy and Safety of TY027, a Treatment for COVID-19, in Humans [Phase 3]

View source ↗

Summary

Phase 3 clinical trial of TY027 for COVID-19 has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • TY027

Snippet

Sponsor: Tychan Pte Ltd. | Conditions: Coronavirus Disease-2019 (COVID-19) | Phase 3 | Status: TERMINATED